ST春天收监管函，退市风险加剧，股价跌至3.12元

Core Viewpoint - ST Chuntian (600381.SH) is facing significant regulatory scrutiny due to potential violations related to revenue recognition, financial health, and related party transactions, which could lead to delisting risks [1][2][4]. Regulatory Concerns - The Shanghai Stock Exchange issued a regulatory letter on February 6, 2026, focusing on three main issues: compliance of revenue recognition, verification of deducted revenue, and risks associated with fund occupation [1]. - The company reported a substantial increase in revenue for Q4 2025, estimated between 130 million to 158 million yuan, which accounts for nearly 40% of the annual total, raising questions about its legitimacy [1]. - The company is required to provide evidence of matching cash flow, goods flow, and terminal sales to rule out any related party transactions or attempts to evade delisting [1]. Financial Health and Delisting Risks - The company is at risk of financial delisting if its deducted revenue falls below 300 million yuan and if it reports a negative net profit, projected between -44 million to -59.5 million yuan for 2025 [2]. - An audit opinion could lead to delisting if the company fails to recover loans, resulting in an audit report that cannot express an opinion [3]. - Regulatory scrutiny may escalate to delisting if significant illegal activities, such as fund occupation, are confirmed [4]. Audit and Compliance - The annual audit firm has indicated uncertainty regarding the company's ability to eliminate delisting risks, and the company must respond to the regulatory letter within ten trading days [5]. Stock Performance - The stock price has experienced a continuous decline since January 28, 2026, following the announcement of expected losses and delisting risks, with a closing price of 3.16 yuan and a total market value of 1.855 billion yuan [6]. - As of February 24, 2026, the stock price slightly rebounded to 3.12 yuan, but it remains approximately 11% lower than the early February peak, with a trading range fluctuation of 17.09% [6]. Market Sentiment - On February 24, 2026, there was a net outflow of 2.4076 million yuan from institutional investors, while retail investors saw a net inflow of the same amount, indicating significant market divergence [7]. Compliance History - The company has a history of disclosure violations, having been publicly reprimanded by the Shanghai Stock Exchange in June 2025 for inaccuracies in its 2024 earnings forecast, highlighting internal control failures [8]. - The sustainability of the company's business is in question, with ongoing doubts about revenue recognition in its cordyceps business and intense competition in its liquor business, leading to growth bottlenecks across its three main sectors [8]. Key Timelines - The company must complete its response to the regulatory letter by late February 2026, with the 2025 audit report expected to be disclosed by the end of April, which will directly impact the stock's listing status [8].